Showing results (181-190 of 194) with videos related to
Sort By:
Pageof 20
Open Forum Infectious Diseases|June 3, 2026
Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized TrialHilda Angela Mujuru, Ellen White, Adeodata R Kekitiinwa, et al.Ebiomedicine|September 27, 2025
Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trialLisanne A H Bevers, Gabriela Toledo, Muzamil Kisekka, et al.The Lancet. HIV|November 28, 2025
Virological and drug-resistance outcomes for people living with HIV initiating or switching to tenofovir, lamivudine, and dolutegravir in six PEPFAR-supported countries: a prospective cohort studyJean Bernard Marc, Caitlyn McCarthy, Carole L Wallis, et al.The Lancet. Child & Adolescent Health|August 10, 2023
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trialAnna Turkova, Ellen White, Adeodata R Kekitiinwa, et al.Contemporary Clinical Trials|April 18, 2024
D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 yearsAnna Turkova, Man K Chan, Cissy Kityo, et al.The Lancet. HIV|April 10, 2026
Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trialAdeodata R Kekitiinwa, Angus Jennings, Mutsa Bwakura-Dangarembizi, et al.Plos One|June 17, 2021
Feasibility of collecting and processing of COVID-19 convalescent plasma for treatment of COVID-19 in UgandaWinters Muttamba, John Lusiba, Loryndah Olive Namakula, et al.Journal of the International AIDS Society|September 28, 2023
Effect of dolutegravir on folate, vitamin B12 and mean corpuscular volume levels among children and adolescents with HIV: a sub-study of the ODYSSEY randomized controlled trialLinda Namutebi Barlow-Mosha, Grace Miriam Ahimbisibwe, Elizabeth Chappell, et al.The Journal of Clinical Investigation|May 22, 2018
Lymphoid tissue fibrosis is associated with impaired vaccine responsesCissy Kityo, Krystelle Nganou Makamdop, Meghan Rothenberger, et al.Nature Medicine|October 3, 2017
Defining total-body AIDS-virus burden with implications for curative strategiesJacob D Estes, Cissy Kityo, Francis Ssali, et al.Pageof 20